Aiming to achieve an enhanced therapeutic efficacy and abrogate the treatment-associated adverse events of PD1/PD-L1 blockade, several pilot interventional strategies are currently underway to probe into the feasibility in manipulating gut microbes in cancer patients based on prior microbiota modulatory experience applied in other disorders. This evidence concerns the gene PDCD1 and cancer.